Recent Updates
Recently added Catalysts

CAR2 Anti-CD38 A2 CAR-T Cells

Phase 1

Relapsed or Refractory Multiple Myeloma | Cell Therapies | Oncology |Sorrento Therapeutics, Inc.|Trials Updated: Mar 16, 2022

CAR2 Anti-CD38 A2 CAR-T Cells development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Mar 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment10

FDA Designations

No designations recorded

CAR2 Anti-CD38 A2 CAR-T Cells clinical trials

CAR2 Anti-CD38 A2 CAR-T Cells · 1 trial · 1 indication

Phase 1 1
NCT03464916Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma PatientsRelapsed or Refractory Multiple Myeloma
COMPLETED10 Analytics
PHASE1COMPLETED
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Relapsed or Refractory Multiple Myeloma
NCT0346491610
Unlock trial analytics

Study Endpoints

Primary Endpoints

Determine the MTD
28 days

The MTD is assessed according to a 3+3 dose-escalation design by the occurrence of treatment-emergent dose-limiting toxicities during the 28-day Treatment Period in the dose-escalation phase of the study

Secondary Endpoints

Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the Cmax
28 days
Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the AUC
28 days
Evaluate the safety of Anti-CD38 A2 CAR-T cells in Patients with RRMM by incidence of treatment-emergent adverse events
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CAR2 Anti-CD38 A2 CAR-T CellsEXPERIMENTALRelapsed or Refractory Multiple Myeloma

Interventions

NameTypeDescription
CAR2 Anti-CD38 A2 CAR-T CellsBIOLOGICALAutologous IV infusion; dose-escalation
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * The patient must either have relapsed refractory multiple myeloma (RRMM) after receiving prior lines of anti-myeloma treatments that included at least lenalidomide (Revlimid®), pomalidomide (Pomalyst®), bortezomib (Velcade®), carfilzomib (Kyprolis®), and daratumumab (Darzalex®...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 338 trials (matched to "Relapsed or Refractory Multiple Myeloma")

Top 20 of 25 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV18PHASE3Venetoclax, Etentamig, Elotuzumab, TNB-383B, ABBV-2001
Johnson & JohnsonJNJ37PHASE3Talquetamab, Teclistamab, Bortezomib, Cilta-cel, Daratumumab
Gilead Sciences, Inc.GILD5PHASE3anitocabtagene-autoleucel
Bristol-Myers Squibb CompanyBMY21PHASE3Iberdomide, Lenalidomide, Mezigdomide, idecabtagene vicleucel, Arlocabtagene autoleucel
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3Gammagard Liquid, Ixazomib
GSK plc Sponsored ADRGSK24PHASE3Belantamab mafodotin, GSK3174998, Feladilimab, Dostarlimab, GSK2857916 with Pomalidomide and Dexamethasone
Regeneron Pharmaceuticals, Inc.REGN11PHASE3linvoseltamab, REGN17372, REGN7945, Fianlimab, Cemiplimab
Sanofi SA Sponsored ADRSNY16PHASE3Isatuximab, Pegenzileukin, SAR439459, Belumosudil, SAR446523
Pfizer Inc.PFE15PHASE3Elranatamab, Axitinib, Bosutinib, Crizotinib, Palbociclib
AstraZeneca PLCAZN8PHASE3AZD0120, AZD0305, GC012F, AZD4045
Ida Bruun KristensenKPTIQ7PHASE3Selinexor
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
Hoffmann-La RocheRHHBY11PHASE3Cevostamab, Tocilizumab, XmAb24306, RO7875913, P-BCMA-ALLO1 CAR-T cells
BeOne Medicines Ltd. Sponsored ADRONC1PHASE2Sonrotoclax
GeoVax Labs, Inc.GOVX1PHASE2GEO-CM04S1
C4 Therapeutics, Inc.CCCC3PHASE2cemsidomide
Moderna, Inc.MRNA1PHASE2mRNA-2808
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I-131
Novartis AG Sponsored ADRNVS1PHASE3Dabrafenib, trametinib
Incyte CorporationINCY2PHASE1Ruxolitinib
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Sorrento Therapeutics, Inc. (SRNE)Pipeline, catalysts, financials, insiders and newsRelapsed or Refractory Multiple Myeloma disease mapEvery company developing for Relapsed or Refractory Multiple Myeloma, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track